Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Osteoporosis 5Prostatic Neoplasms 3Breast Neoplasms 3Hypogonadism 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Genetic Diseases, Inborn 1Esophageal Neoplasms 1Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

testosterone undecanoate 4Testosterone 3Alendronate 2testosterone 17 beta-cypionate 1Triptorelin Pamoate 1Testosterone Propionate 1Tamoxifen 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Practice Guidelines as Topic 1Pioglitazone 1Orchiectomy 1Observation 1Methyltestosterone 1Mental Status and Dementia Tests 1Gonadotropin-Releasing Hormone 1Gels 1Drug Evaluation 1Clomiphene 1Castor Oil 1Blood Specimen Collection 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hypogonadism × Alendronate × Clear all
NCT00177619 2014-02-11

Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study)

University of Pittsburgh

Phase 3 Completed
120 enrolled
Genitourinary

Hypogonadism, Prostatic Neoplasms

NCT00048841 2010-03-02

Prevention of Osteoporosis in Men With Prostate Cancer

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Phase 3 Completed
112 enrolled
Genitourinary

Hypogonadism, Osteoporosis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡